↓ Skip to main content

Dove Medical Press

Article Metrics

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based…

Overview of attention for article published in Infection and Drug Resistance, May 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
20 Mendeley
Title
Defining the potency of amikacin against <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, <em>Pseudomonas aeruginosa</em>, and <em>Acinetobacter baumannii</em> derived from Chinese hospitals using CLSI and inhalation-based breakpoints
Published in
Infection and Drug Resistance, May 2018
DOI 10.2147/idr.s161636
Pubmed ID
Authors

Joseph L Kuti, Qi Wang, Hongbin Chen, Henan Li, Hui Wang, David P Nicolau

Abstract

We report the in vitro activity of amikacin and comparators against Gram-negative bacteria collected from blood and respiratory specimens in China during a 1-year period between December 2015 and December 2016. Minimum inhibitory concentrations (MICs) were determined by agar dilution methods using Clinical and Laboratory Standards Institute (CLSI) guidelines, and susceptibility was assessed using CLSI breakpoints, except for tigecycline against Enterobacteriaceae. A pharmacodynamic threshold MIC ≤ 256 mg/L was also applied for amikacin since its inhalation formulation has demonstrated activity up to these MICs. For Escherichia coli, including extended-spectrum beta-lactamase (ESBL)-producing isolates (45.7% of population), amikacin demonstrated excellent activity (93.0%-94.7% susceptible) similar to tigecycline, piperacillin/tazobactam, and the carbapenems. Against Klebsiella pneumoniae, only tigecycline retained susceptibility >90%; amikacin inhibited 83.7% and 71.1% of the total and ESBL-producing (24.2%) populations at its breakpoint, respectively. Amikacin susceptibility against Pseudomonas aeruginosa was 91.1%, and only polymyxin B (100%) achieved higher susceptibility rates. Susceptibility declined to 80.9% and 54.5% against carbapenem- and multidrug-resistant (MDR) isolates, respectively. Finally, MDR was very common (84.0%) among Acinetobacter baumannii, with amikacin susceptibility at 30.5% for all isolates and 17.3% for MDR isolates. Since the majority of the amikacin-resistant isolates had amikacin MICs > 256 mg/L, the use of the inhalation pharmacodynamic threshold did not substantially improve the CLSI susceptible value. Amikacin portrayed comparable or better susceptibility rates to most of the tested antibiotics against E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii in China. As few isolates had MICs of 32-256 mg/L, use of the CLSI breakpoint and inhalation pharmacodynamic threshold yielded similar overall susceptibilities.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 30%
Student > Bachelor 3 15%
Student > Ph. D. Student 2 10%
Student > Postgraduate 2 10%
Other 2 10%
Other 1 5%
Unknown 4 20%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 5 25%
Immunology and Microbiology 3 15%
Business, Management and Accounting 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Veterinary Science and Veterinary Medicine 1 5%
Other 2 10%
Unknown 7 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2018.
All research outputs
#9,998,625
of 13,073,426 outputs
Outputs from Infection and Drug Resistance
#237
of 432 outputs
Outputs of similar age
#189,546
of 271,266 outputs
Outputs of similar age from Infection and Drug Resistance
#8
of 12 outputs
Altmetric has tracked 13,073,426 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 432 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,266 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.